Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 14/20 | 0.79 |
| ▸ | THRA | P10827 | 13/20 | 0.79 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25856594 | 0.92 | THRB (0.67) | THRBTHRASLC7A5MEN1CYP3A4 | |
| SCHEMBL281956 | 0.90 | THRB (0.77) | THRBTHRAPTPN1 | |
| SCHEMBL22071776 | 0.89 | THRB (0.62) | THRBTHRASLC7A5MEN1CYP3A4 | |
| SCHEMBL13381665 | 0.89 | THRB (0.61) | THRBTHRASLC7A5MEN1CYP3A4 | |
| SCHEMBL328325 | 0.88 | THRB (1.00) | THRBTHRAPTPN1 | |
| SCHEMBL1457657 | 0.86 | THRB (0.79) | THRBTHRAPTPN1 | |
| SCHEMBL19565202 | 0.86 | THRB (0.59) | THRBTHRASLC7A5MEN1CYP3A4 | |
| SCHEMBL1457659 | 0.85 | THRB (0.77) | THRBTHRAPTPN1 | |
| SCHEMBL24212405 | 0.85 | THRB (0.80) | THRBTHRAPTPN1 | |
| SCHEMBL12824840 | 0.85 | THRB (0.57) | THRBTHRASLC7A5MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | US GOV VETERANS AFFAIRS (US) | 2026-03-19 | — | — | US | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| US-20250188473-A1 | Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | claimed |
| CN-119868564-A | Combined medicine for preventing and/or treating obesity | 海创药业股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2024251233-A1 | USE OF PPAR FULL AGONIST IN COMBINATION WITH THR-β AGONIST IN RESISTING OF METABOLIC-RELATED DISEASES | 成都微芯药业有限公司 | 2024-12-12 | — | — | WO | claimed |
| US-20240410902-A1 | USE OF SOLUBLE TREM2 AS A NON-INVASIVE BIOMARKER FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) | REGION SYDDANMARK (DK) | 2024-12-12 | — | — | US | claimed |
| US-12123001-B2 | Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2024-10-22 | — | — | US | claimed |
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| US-20240197689-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2024-06-20 | — | — | US | claimed |
| EP-4337314-A1 | METHODS OF TREATING LIVER DISEASES WITH PHOSPHODIESTERASE 3B (PDE3B) INHIBITORS | Regeneron Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4259279-A1 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-18 | — | — | EP | claimed |
| EP-4243822-A1 | USE OF PHARMACEUTICAL DOSES OF NIACIN, OR AN ANALOG THEREOF, FOR THE REGRESSION OR REVERSAL OF FIBROSIS AND/OR LIVER CIRRHOSIS | The Regents of The University of California (US) | 2023-09-20 | — | — | EP | claimed |
| WO-2022248363-A1 | USE OF SOLUBLE TREM2 AS A NON-INVASIVE BIOMARKER FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) | SYDDANSK UNIVERSITET (DK) | 2022-12-01 | — | — | WO | claimed |
| US-20220364099-A1 | Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2022-11-17 | — | — | US | claimed |
| WO-2022240783-A1 | METHODS OF TREATING LIVER DISEASES WITH PHOSPHODIESTERASE 3B (PDE3B) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| US-20220313726-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2022-10-06 | — | — | US | claimed |
| WO-2022132666-A1 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| US-20220184114-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2022-06-16 | — | — | US | claimed |
| US-20220152012-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-19 | — | — | US | claimed |
| WO-2022104289-A1 | USE OF PHARMACEUTICAL DOSES OF NIACIN, OR AN ANALOG THEREOF, FOR THE REGRESSION OR REVERSAL OF FIBROSIS AND/OR LIVER CIRRHOSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | INHA, TNNI3, SHBG | THRB 157/4885THRA 879/4885PTPN1 4593/4885 |
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | COL1A1, COL2A1, FN1 | THRB 1462/4885THRA 1368/4885PTPN1 1441/4885 |
| US-20240197689-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | PPARD, FABP1, GOT2 | THRB 181/4885THRA 268/4885PTPN1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.